TheraBionic is developing treatment approaches for cancer based on the use of tumor-specific modulation frequencies, with an initial focus in hepatocellular carcinoma.
Employment range in NC
Primary site activity
All company activities
Products on market
The TheraBionic P1 medical device received European regulatory approval for the treatment of advanced advanced hepatocellular carcinoma in 2018
Products under development
The TheraBionic P1 received Breakthrough Designation from tbe FDA in 2019